The global Intranasal
Drug Delivery Devices Market size is estimated to generate revenues of more
than USD 2.98 billion by 2030, growing at a CAGR of around 12.8%
from 2021 to 2030
The report covers SWOT analysis, market valuation, competitive spectrum,
regional share, and revenue predictions. The report offers an analysis of the global intranasal
drug delivery devices Market for the period 2016 to 2030, wherein 2021 to 2030
is the forecast period and 2020 is considered as the base year.
The wide application portfolio of intranasal drug delivery devices
market is one of factors driving the growth of market worldwide. The global
market is moderately competitive with a blend of global and regional players.
The markets key players invest significantly in R and D to enhance their
offerings. The entire ecosystem is composed of multiple participants. Every
participant of the ecosystem is an equal contributor to the growth of global
market.
Why should
you invest in this report?
If you are aiming to enter the global intranasal
drug delivery devices Market, this report is a comprehensive guide that
provides crystal clear insights into this niche market. All the major
application areas for intranasal drug delivery devices are covered in this
report and information is given on the important regions of the world where
this market is likely to boom during the forecast period of 2021-2030, so that
you can plan your strategies to enter this market accordingly. Besides, through
this report, you can have a complete grasp of the level of competition you will
be facing in this hugely competitive market and if you are an established
player in this market already, this report will help you gauge the strategies
that your competitors have adopted to stay as market leaders in this market.
For new entrants to this market, the voluminous data provided in this report is
invaluable.
Report Structure:
- pertinent
market numbers of the global intranasal drug delivery devices market along
with the CAGR for the forecast period 2021-2030
- detailed
definitions of different types of intranasal drug delivery devices, which
gives clarity about what this market is all about and also defines the
scope of this report
- macroeconomic
factors influencing the global intranasal drug delivery devices market,
along with market opportunity analysis
- key
trends likely to impact the global intranasal drug delivery devices market
- PESTLE
analysis of all the regions as per the market taxonomy
- Porter’s
Five Force Analysis of all the regions as given in the market taxonomy
Global market analysis and forecast:
- the
global intranasal drug delivery devices market analysis and forecast by
product type, by application, by region and others
- key
market metrics such as the BPS analysis, year-on-year growth rates,
absolute dollar opportunity and market attractiveness analysis of the
global intranasal drug delivery devices market
Regional market analysis and forecast:
- Regional
intranasal drug delivery devices market analysis and forecast
- Regional
market dynamics including the drivers, restraints and trends applicable
across different regions in the intranasal drug delivery devices market
along with factors encouraging the growth of this market as well as the
factors hampering the growth of this market
- Regional
trends – both long term and short term
View Full Report@
https://www.precedenceresearch.com/intranasal-drug-delivery-devices-market
Competitive landscape:
- the
competitive landscape of this global report
- information
on the various leading companies in the global market
- a
dashboard view of the key companies operating in the global market along
with their important information and broad strategy adopted to stay as
leaders in the global market
- key
company profiles along with important information such as company details,
company description, product portfolio along with key developments
concerning the company and strategic analysis
Some of the prominent players in intranasal
drug delivery devices market include:
- Johnson & Johnson,
Inc.
- Aptar Pharma Group
- GlaxoSmithKline Plc
- Aegis Therapeutics LLC
- H&T Presspart
Manufacturing Ltd.
- AstraZeneca Plc
- Becton, Dickinson and
Company
- Novartis AG
- Teleflex Incorporated
- Vectura Group Plc.
Market Segmentation:
By System
- Metered Dose
- Multi-Dose Systems
- Unit-Dose Systems
By Container
- Non-Pressurized
Containers
- Pressurized Containers
By Application
- Chronic Obstructive
Pulmonary Disease (COPD)
- Rhinitis
- Cystic Fibrosis
- Nasal Congestion
- Asthma
- Others
By End User
- Ambulatory Surgical
Centers
- Clinics
- Hospitals
- Others
By Geography
North America
- U.S.
- Canada
Europe
- Germany
- France
- United Kingdom
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Southeast Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa
(MEA)
- GCC
- North Africa
- South Africa
- Rest of Middle East
& Africa
Research Methodology
In this report, historical data, primary
responses and public domain data has been thoroughly analyzed to infer the
market size. Revenue of companies operating in the global market has been
benchmarked to ascertain the market size for the base year. Macroeconomic
indicators such as GDP and industry growth have been considered to determine
the market size for the forecast period. The historical growth trend of end-use
industries, market participants’ performance, as well as the present
macro-economic outlook has been taken into consideration for estimating the
overall market trend forecast. This data is then validated using the
triangulation method and extensively scrutinized using advanced tools to garner
quantitative and qualitative insights into the global intranasal drug delivery
devices.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research
Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations
Chapter 3. Executive
Summary
3.1. Market Snapshot
Chapter 4. Intranasal
Drug Delivery Devices Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
Chapter 5. COVID 19
Impact on Intranasal Drug Delivery Devices Market
5.1. Covid-19: Intranasal Drug Delivery Devices
Industry Impact
5.2. Intranasal Drug Delivery Devices Business Impact Assessment:
Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Intranasal Drug Delivery Devices
Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Intranasal Drug Delivery Devices Market
Players to deal with Covid-19 Pandemic Scenario
Chapter 6. Intranasal
Drug Delivery Devices Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. High prevalence of cardiovascular diseases
6.1.1.2. Patent expiration of popular drugs, increased cases of
cancer and diabetes
6.1.2. Market Restraints
6.1.2.1. Complications Associated with the Overuse
6.1.3. Market Opportunities
6.1.3.1. Growing adoption of self-administration practices
6.1.3.2. Technological advancements
Chapter 7. Global
Intranasal Drug Delivery Devices Market: Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Intranasal Drug Delivery Devices Market Revenue by Market
Players (2016 -2019)
7.1.1.2. Intranasal Drug Delivery Devices Market Revenue Market
Share by Market Players (2016 -2019)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, System
Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users
Chapter 8. Global
Intranasal Drug Delivery Devices Market, By System
8.1. Intranasal Drug Delivery Devices Market, by
System, 2016-2027
8.1.1. Metered Dose
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Multi-Dose Systems
8.1.2.1. Market Revenue and Forecast (2016-2027)
8.1.3. Unit-Dose Systems
8.1.3.1. Market Revenue and Forecast (2016-2027)
Chapter 9. Global
Intranasal Drug Delivery Devices Market, By Container
9.1. Intranasal Drug Delivery Devices Market, by
Container, 2016-2027
9.1.1. Non-Pressurized Containers
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Pressurized Containers
9.1.2.1. Market Revenue and Forecast (2016-2027)
Chapter 10. Global
Intranasal Drug Delivery Devices Market, By Application
10.1. Intranasal Drug Delivery Devices Market, by
Application, 2016-2027
10.1.1. Chronic Obstructive Pulmonary Disease (COPD)
10.1.1.1. Market Revenue and Forecast (2016-2027)
10.1.2. Rhinitis
10.1.2.1. Market Revenue and Forecast (2016-2027)
10.1.3. Cystic Fibrosis
10.1.3.1. Market Revenue and Forecast (2016-2027)
10.1.4. Nasal Congestion
10.1.4.1. Market Revenue and Forecast (2016-2027)
10.1.5. Asthma
10.1.5.1. Market Revenue and Forecast (2016-2027)
10.1.6. Others
10.1.6.1. Market Revenue and Forecast (2016-2027)
Chapter 11. Global
Intranasal Drug Delivery Devices Market, By End User
11.1. Intranasal Drug Delivery Devices Market, by
End User, 2016-2027
11.1.1. Ambulatory Surgical Centers
11.1.1.1. Market Revenue and Forecast (2016-2027)
11.1.2. Clinics
11.1.2.1. Market Revenue and Forecast (2016-2027)
11.1.3. Hospitals
11.1.3.1. Market Revenue and Forecast (2016-2027)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2016-2027)
Chapter 12. Global
Intranasal Drug Delivery DevicesMarket, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue Forecast by System(2016-2027)
12.1.2. Market Revenue Forecast by Container(2016-2027)
12.1.3. Market Revenue Forecast by Application(2016-2027)
12.1.4. Market Revenue Forecast by End User (2016-2027)
12.1.5. U.S
12.1.5.1. Market Revenue Forecast (2016-2027)
12.1.6. Canada
12.1.6.1. Market Revenue Forecast (2016-2027)
12.2. Europe
12.2.1. Market Revenue Forecast by System (2016-2027)
12.2.2. Market Revenue Forecast by Container (2016-2027)
12.2.3. Market Revenue Forecast by Application (2016-2027)
12.2.4. Market Revenue Forecast by End User (2016-2027)
12.2.5. UK
12.2.5.1. Market Revenue Forecast (2016-2027)
12.2.6. Germany
12.2.6.1. Market Revenue Forecast (2016-2027)
12.2.7. France
12.2.7.1. Market Revenue Forecast (2016-2027)
12.2.8. Rest of EU
12.2.8.1. Market Revenue Forecast (2016-2027)
12.3. Asia Pacific (APAC)
12.3.1. Market Revenue Forecast by System (2016-2027)
12.3.2. Market Revenue Forecast by Container (2016-2027)
12.3.3. Market Revenue Forecast by Application (2016-2027)
12.3.4. Market Revenue Forecast by End User (2016-2027)
12.3.5. China
12.3.5.1. Market Revenue Forecast (2016-2027)
12.3.6. India
12.3.6.1. Market Revenue Forecast (2016-2027)
12.3.7. Japan
12.3.7.1. Market Revenue Forecast (2016-2027)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue Forecast (2016-2027)
12.4. LATAM
12.4.1. Market Revenue Forecast by System (2016-2027)
12.4.2. Market Revenue Forecast by Container (2016-2027)
12.4.3. Market Revenue Forecast by Application (2016-2027)
12.4.4. Market Revenue Forecast by End User (2016-2027)
12.4.5. Brazil
12.4.5.1. Market Revenue Forecast (2016-2027)
12.4.6. Rest of LATAM
12.4.6.1. Market Revenue Forecast (2016-2027)
12.5. Middle East and Africa (MEA)
12.5.1. Market Revenue Forecast by System (2016-2027)
12.5.2. Market Revenue Forecast by Container (2016-2027)
12.5.3. Market Revenue Forecast by Application (2016-2027)
12.5.4. Market Revenue Forecast by End User (2016-2027)
12.5.5. GCC
12.5.5.1. Market Revenue Forecast (2016-2027)
12.5.6. North Africa
12.5.6.1. Market Revenue Forecast (2016-2027)
12.5.7. South Africa
12.5.7.1. Market Revenue Forecast (2016-2027)
12.5.8. Rest of MEA
12.5.8.1. Market Revenue Forecast (2016-2027)
Chapter 13. Company
Profiles
13.1. Johnson & Johnson, Inc.
13.1.1. Company Overview, Business Information, Regional Presence
13.1.2. Product Portfolio Analysis
13.1.2.1. Product Details, Specification, Application
13.1.3. Revenue, Price, and Gross Margin (2015-2020)
13.1.4. Recent Developments and Strategies
13.2. Aptar Pharma Group
13.2.1. Company Overview, Business Information, Regional Presence
13.2.2. Product Portfolio Analysis
13.2.2.1. Product Details, Specification, Application
13.2.3. Revenue, Price, and Gross Margin (2015-2020)
13.2.4. Recent Developments and Strategies
13.3. GlaxoSmithKline Plc
13.3.1. Company Overview, Business Information, Regional Presence
13.3.2. Product Portfolio Analysis
13.3.2.1. Product Details, Specification, Application
13.3.3. Revenue, Price, and Gross Margin (2015-2020)
13.3.4. Recent Developments and Strategies
13.4. Aegis Therapeutics LLC
13.4.1. Company Overview, Business Information, Regional Presence
13.4.2. Product Portfolio Analysis
13.4.2.1. Product Details, Specification, Application
13.4.3. Revenue, Price, and Gross Margin (2015-2020)
13.4.4. Recent Developments and Strategies
13.5. H&T Presspart Manufacturing Ltd.
13.5.1. Company Overview, Business Information, Regional Presence
13.5.2. Product Portfolio Analysis
13.5.2.1. Product Details, Specification, Application
13.5.3. Revenue, Price, and Gross Margin (2015-2020)
13.5.4. Recent Developments and Strategies
13.6. AstraZeneca Plc
13.6.1. Company Overview, Business Information, Regional Presence
13.6.2. Product Portfolio Analysis
13.6.2.1. Product Details, Specification, Application
13.6.3. Revenue, Price, and Gross Margin (2015-2020)
13.6.4. Recent Developments and Strategies
13.7. Becton, Dickinson and Company
13.7.1. Company Overview, Business Information, Regional Presence
13.7.2. Product Portfolio Analysis
13.7.2.1. Product Details, Specification, Application
13.7.3. Revenue, Price, and Gross Margin (2015-2020)
13.7.4. Recent Developments and Strategies
13.8. Novartis AG
13.8.1. Company Overview, Business Information, Regional Presence
13.8.2. Product Portfolio Analysis
13.8.2.1. Product Details, Specification, Application
13.8.3. Revenue, Price, and Gross Margin (2015-2020)
13.8.4. Recent Developments and Strategies
13.9. Teleflex Incorporated
13.9.1. Company Overview, Business Information, Regional Presence
13.9.2. Product Portfolio Analysis
13.9.2.1. Product Details, Specification, Application
13.9.3. Revenue, Price, and Gross Margin (2015-2020)
13.9.4. Recent Developments and Strategies
13.10. Vectura Group Plc.
13.10.1. Company Overview, Business Information, Regional Presence
13.10.2. Product Portfolio Analysis
13.10.2.1. Product Details, Specification, Application
13.10.3. Revenue, Price, and Gross Margin (2015-2020)
13.10.4. Recent Developments and Strategies
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: http://www.marketstatsnews.com/




0 comments:
Post a Comment